Pfizer (PFE) is facing significant challenges, with its stock down over 50% from pandemic highs, but this could present a buying opportunity for long-term investors. The decline follows an initial surge driven by COVID vaccine sales, which led to overly optimistic projections about sustained demand. As patent expirations loom for key drugs and a recent setback in developing a GLP-1 weight loss drug adds to investor concerns, the market is currently pricing Pfizer as if it won’t recover.
Despite these headwinds, Pfizer is actively pursuing innovation, including acquiring a competitor with a promising GLP-1 drug and advancing multiple drug candidates across various therapeutic areas. With plans for up to 20 pivotal studies in 2026 and a solid dividend yield of 6.5%, the company is strategically positioned to rebound.
For market professionals, this situation highlights a critical takeaway: Pfizer’s current valuation may offer a rare entry point into a historically resilient company, making it a potential long-term investment despite present challenges.
Source: fool.com